Johanna Hynninen

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker (2016)

PLoS ONE

Laura Lehtinen, Pia Vesterkvist, Pia Roering, Taina Korpela, Liisa Hattara, Katja Kaipio, John-Patrick Mpindi, Johanna Hynninen, Annika Auranen, Ben Davidson, Caj Haglund, Kristiina Iljin, Seija Grenman, Harri Siitari, Olli Carpen

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Characterization of ascites and tumor-derived ovarian cancer stem-like cells (2016)

Clinical Cancer Research

Kaipio K, Chen P, Huhtinen K, Mikkonen P, Ostling P, Mpindi JP, Lehtinen L, Roering P, Korpela T, Wennerberg K, Yadav B, Aittokallio T, Kulesskiy E, Hynninen J, Auranen A, Grenman S, Hautaniemi S, Carpen O

(O2 Muu julkaisu )

A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources (2016)

Clinical Chemistry

Gidwani Kamlesh, Huhtinen Kaisa, Kekki Henna, van Vliet Sandra, Hynninen Johanna, Koivuviita Niina, Perheentupa Antti, Poutanen Matti, Auranen Annika, Grenman Seija, Lamminmaki Urpo, Carpen Olli, van Kooyk Yvette, Pettersson Kim

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

(18)F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer (2016)

Gynecologic Oncology

Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy (2015)

Cancer Research

Chen P, Huhtinen K, Kaipio K, Mikkonen P, Aittomaki V, Lindell R, Hynninen J, Auranen A, Grenman S, Lehtonen R, Carpen O, Hautaniemi S

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Advanced epithelial ovarian cancer – studies on preoperative [18F] FDG PET/CT and HE4 profile during primary chemotherapy (2015)

Hynninen Johanna

(Artikkeliväitöskirja (G5))

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. (2014)

Tumor Biology

Vallius Tuulia, Hynninen Johanna, Auranen Annika, Carpén Olli, Matomäki Jaakko, Oksa Sinikka, Virtanen Johanna, Grénman Seija

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Characterization of primary high-grade serous ovarian cancer cell lines: Cell line and growth condition specific differences in stem cell marker expression and high-throughput drug screening (2013)

Clinical Cancer Research

Roering P, Mikkonen P, Kaipio K, Huhtinen K, Hynninen J, Auranen A, Kulesskiy E, Yadav B, Aittokallio T, Grenman S, Wennerberg K, Carpen O

(O2 Muu julkaisu )

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? (2013)

Gynecologic Oncology

Hynninen J, Lavonius M, Oksa S, Grénman S, Carpén O, Auranen A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer (2013)

Gynecologic Oncology

Hynninen J, Kemppainen J, Lavonius M, Virtanen J, Matomaki J, Oksa S, Carpen O, Grenman S, Seppanen M, Auranen A

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Ota yhteyttä

Linkit

Julkaisut

Järjestä:

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker (2016)

Characterization of ascites and tumor-derived ovarian cancer stem-like cells (2016)

A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources (2016)

(18)F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer (2016)

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy (2015)

Advanced epithelial ovarian cancer – studies on preoperative [18F] FDG PET/CT and HE4 profile during primary chemotherapy (2015)

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. (2014)

Characterization of primary high-grade serous ovarian cancer cell lines: Cell line and growth condition specific differences in stem cell marker expression and high-throughput drug screening (2013)

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? (2013)

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer (2013)